Absci Corporation (ABSI) vs Novavax, Inc. (NVAX)

Absci Corporation and Novavax, Inc. are both Biotechnology companies. Absci Corporation and Novavax, Inc. are of similar size ($1.8B and $1.8B). Novavax, Inc. grew revenue faster over the last twelve months: −61.6% against −62.3%. Novavax, Inc. has the higher net margin (−59.9% vs −7,756.4%) and the higher return on invested capital (0.00% vs −174.7%). Across the 17 metrics below, Novavax, Inc. leads on 14 and Absci Corporation on 3.

Valuation

Metric ABSI NVAX Biotechnology median
P/E n/m n/m 7.88
P/S 982.56 4.23 11.47
P/B 6.23 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 853.84 3.20 10.73
Earnings yield (8.21%) (14.30%) (28.84%)
Free cash flow yield (7.09%) (2.52%) (23.03%)

Profitability

Metric ABSI NVAX Biotechnology median
Gross margin 100.00% 78.60% 65.16%
Operating margin (8,084.50%) (56.58%) 0.00%
Net margin (7,756.37%) (59.87%) 0.00%
Free cash flow margin (6,969.83%) (10.20%) 0.00%
Return on equity (57.72%) 323.66% (57.72%)
Return on assets (50.57%) (21.62%) (49.22%)
Return on invested capital (174.74%) 0.00% 0.00%

Growth

Metric ABSI NVAX Biotechnology median
Revenue growth (TTM) (62.28%) (61.64%) 5.64%
EPS growth (last fiscal year) 10.64% 309.76% —
Revenue growth, 5-year CAGR (10.14%) 18.76% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABSI NVAX Biotechnology median
Debt to equity 0.00 (1.54) 0.00
Current ratio 10.63 2.33 4.73
Net debt to EBITDA 1.32 (1.04) 0.96

Dividend

Metric ABSI NVAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ABSI NVAX Biotechnology median
Market cap 1.81b 1.75b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack